NICE backs Ferring’s Firmagon
Men with advanced hormone-dependent prostate cancer and spinal metastases are to gain routine access to Ferring’s Firmagon on the NHS after a NICE u-turn saw the cost regulator issue final draft guidance endorsing its use.
Read More
